First etanercept biosimilar available to prescribe

Benepali (etanercept) launches this week, providing prescribers with a biosimilar version of the TNF-targeting biologic etanercept. The 50mg prefilled pens and syringes are approved to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis in adults.

Etanercept has been shown to slow the progression of joint damage and improve physical function in patients with rheumatoid arthritis. | iStock
Etanercept has been shown to slow the progression of joint damage and improve physical function in patients with rheumatoid arthritis. | iStock

Etanercept is a soluble TNF receptor fusion protein that abrogates the pro-inflammatory effects of TNF signalling.

Further information
View Benepali drug record
Summary of Product Characteristics
Manufacturer: Biogen Idec

As a biosimilar medicine, Benepali was shown to be comparable to the reference etanercept product, Enbrel, in terms of quality, biological activity, structural characteristics, safety and efficacy. 

Clinical equivalence of Benepali to Enbrel was demonstrated in a double-blind, phase III study in 596 patients with moderate to severe active rheumatoid arthritis despite methotrexate therapy. Participants were randomised to receive Enbrel or Benepali 50mg once weekly for up to 52 weeks.

Analysis of the per-protocol population showed an ACR20 response rate at 24 weeks (primary endpoint) of 78.1% in the Benepali arm and 80.3% in the Enbrel arm, meeting the predefined criterion for therapeutic equivalence. The safety profile of Benepali was comparable to that of Enbrel.

"For more than 15 years anti-TNF therapies have revolutionized the care and outlook for patients living with chronic inflammatory diseases such as RA. However, access to these highly-effective treatments has been restricted by high costs," said Professor Peter Taylor, Norman Collisson Professor of Musculoskeletal Sciences, Kennedy Institute of Rheumatology, University of Oxford.

"The development of biosimilar drugs is a welcome solution to help alleviate some challenges with access. The newly-approved treatment Benepali has similar quality, efficacy, and a comparable safety and immunogenicity profile to Enbrel."

Biosimilar medicines should be prescribed by brand, according to MHRA advice.

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.